Cambridge Enterprise, University of Cambridge
Cambridge Enterprise exists to help University of Cambridge inventors, innovators and entrepreneurs make their ideas and concepts more commercially successful for the benefit of society, the UK economy, the inventors and the University.
|Address:||Hauser Forum, 3 Charles Babbage Road, Cambridge|
|Membership type:||Cambridge University Department|
Cambridge Enterprise Limited is responsible for the commercialisation of University of Cambridge intellectual property and is a wholly owned subsidiary of the University. Activities include management and licensing of intellectual property and patents, proof of concept funding and support for University staff and research groups wishing to provide expert advice or facilities to public and private sector organisations. Cambridge Enterprise provides access to angel and early stage capital through the Cambridge Enterprise Seed Funds and Cambridge Enterprise Venture Partners, and offers business planning, mentoring and other related programmes.
The University leads the world in transformative research and Cambridge Enterprise is well placed to support the academics to find the best commercialisation route for their innovations either through licensing, company creation or consultancy. Income over the past three years exceeded £27 million, of which over £22 million was distributed to University academics and departments, with the remainder reinvested in patent assets, seed fund pools and support for knowledge and technology transfer services to the University.
The website contains information on technologies available for licensing and details of companies formed with technology arising from the University of Cambridge. Cambridge Enterprise is also responsible for the commercial licensing of research reagents owned by the University.
University of Cambridge spin-out Breathing Buildings has been recognised as one of ten companies driving change in the energy sector, thanks to its natural ventilation technology which can reduce heating bills by as much as 50%.
10 April 2014Read in full
The University laboratories at the Stevenage Bioscience Catalyst, where Cambridge researchers are developing potential new treatments for MS, animal allergies and hypersensitivity to heat in collaboration with industry, are now officially open.
24 March 2014Read in full
The largest biometric programme in history – collecting iris and fingerprint patterns of 1.2 billion people in three years – aims to improve the quality of life for some of India’s most disadvantaged and marginalised citizens by “giving the poor an identity.”
7 February 2014Read in full
A new long-range wireless tag detection system, with potential applications in health care, environmental protection and goods tracking, can pinpoint items with near 100 per cent accuracy over a much wider range than current systems.
24 January 2014Read in full
The University seed funds, which support new companies based on Cambridge research, saw their biggest-ever return this year, according to annual results from Cambridge Enterprise, the University’s commercialisation arm. The return of nearly £7.7 million, which will be used to support future Cambridge spin-out companies, resulted from the sale of biotechnology company BlueGnome to US-based genetic analysis company Illumina for $95 million.
21 January 2014Read in full